| Company Name: |
Innovassynth Technologies (I) Ltd.
|
| Tel: |
+91-2192260100 +91-7208872197 |
| Email: |
marketing@innovassynth.com |
| Products Intro: |
Product Name:Mipomersen sodium
Purity:98% Package:1 kg,5 kg, 10 kg,25kg and 1 MT
|
| Company Name: |
EnliPharma Technology Co., Ltd
|
| Tel: |
0551-66399836 18955197623 |
| Email: |
sales@enlipharma.com |
| Products Intro: |
Product Name:MipoMersen sodiuM
CAS:629167-92-6
Purity:>97% Package:1g,5g,100g,500g,1Kg,10kg
|
| Company Name: |
CLEARSYNTH LABS LTD.
|
| Tel: |
+91-22-45045900 |
| Email: |
sales@clearsynth.com |
| Products Intro: |
Product Name:Mipomersen Sodium
CAS:629167-92-6
|
|
| | MipoMersen sodiuM Basic information |
| | MipoMersen sodiuM Chemical Properties |
| storage temp. | Store at -20°C |
| | MipoMersen sodiuM Usage And Synthesis |
| Description | Mipomersen is a 20-mer phosphorothioate oligonuleotide with underlined residues containing 2'-O-(2-methoxyethyl) nucleosides; all other residues are 2'-deoxynucleosides. Substitution at the 5-position of cytosine (C) and uracil (U) bases with a methyl group is indicated by MeC or MeU. Mipomersen (also known as ISIS 301012) was approved with orphan drug status by the US FDA in January 2013 as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDLC), apolipoprotein B (Apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH). Mipomersen is an anti-sense oligonucleotide (ASO) designed to inhibit Apo B100 transcription by Watson Crick pairing to the mRNA sequence to target the complex for silencing and elimination, often via RNase H1 degradation.Mipomersen is synthesized via solid-phase nucleotide synthesis involving sequential addition of nucleotide phosphoramidates, with subsequent phosphorothiolation via phenylacetyldisulfide. | | Originator | ISIS Pharmaceuticals (United States) | | Brand name | Kynamro |
| | MipoMersen sodiuM Preparation Products And Raw materials |
|